SLC2A1 and ovarian cancer: To examine whether ovarian cancer cells undergo metabolic reprogramming when cultured in OCM or fatty acid-enriched medium, we first used STF31, an inhibitor of the glucose transporter GLUT1, to inhibit the use of glycolysis to generate energy for supporting ovarian cancer cell growth.